Predicting the efficacy of COVID-19 convalescent plasma donor units with the Lumit Dx anti-receptor binding domain assay

BACKGROUND: The novel coronavirus SARS-CoV2 that causes COVID-19 has resulted in the death of more than 2.5 million people, but no cure exists. Although passive immunization with COVID-19 convalescent plasma (CCP) provides a safe and viable therapeutic option, the selection of optimal units for ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Janaka, Sanath Kumar, Clark, Natasha M., Evans, David T., Mou, Huihui, Farzan, Michael, Connor, Joseph P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312954/
https://www.ncbi.nlm.nih.gov/pubmed/34310603
http://dx.doi.org/10.1371/journal.pone.0253551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312954/
https://www.ncbi.nlm.nih.gov/pubmed/34310603
http://dx.doi.org/10.1371/journal.pone.0253551

Ejemplares similares